Parameters | BMIhisto+and normal karyotype | Abnormal karyotypes | ||
---|---|---|---|---|
(n = 135) | 1 numerical | 1 structural | ≥ 2 abnormalities | |
 |  | (n = 42) | (n = 12) | (n = 138) |
Age (years) | Â | Â | Â | Â |
  Median (range) | 58 (2–86) | 67 (11–83) * | 56 (45–77) | 60 (10–86) |
  Age > 60 yr | 64/135 (47.4) | 34/42 (81.0) * | 5/12 (41.7) | 66/138 (47.8) |
Gender (male/female) | 59/76 (43.7) | 35/7 (83.3) * | 10/2 (83.3) * | 76/62 (55.1) |
ECOG ≥ 2 | 26/135 (19.3) | 6/42 (14.3) | 0/12 (0) | 62/138 (44.9) * |
High serum LDH | 95/135 (70.4) | 16/42 (38.1) * | 6/12 (50.0) | 123/138 (89.1) * |
B symptoms | 50/135 (37.0) | 7/42 (16.7) * | 6/12 (50.0) | 98/138 (71.0) * |
Stage 3 or 4, | 123/135 (91.1) | 18/42 (42.9) * | 9/12 (75.0) | 126/138 (91.3) |
excluding BM status | Â | Â | Â | Â |
Extranodal ≥ 2 sites | 89/135 (65.9) | 13/42 (31.0) * | 5/12 (41.7) | 112/138 (81.2) * |
IPI risk | Â | Â | Â | Â |
  Low | 0/135 (0) | 16/42 (38.1) | 1/12 (8.3) | 1/138 (0.7) |
  Low/intermediate | 28/135 (20.7) | 10/42 (23.8) | 5/12 (41.7) | 4/138 (2.9) |
  High/intermediate | 65/135 (48.2) | 10/42 (23.8) | 6/12 (50.0) | 58/138 (42.0) |
  High | 42/135 (31.1) | 6/42 (14.3) * | 0/12 (0) * | 75/138 (54.4) * |
Non-GCB type | 46/73 (63.0) | 17/26 (65.4) | 3/8 (37.5) | 53/88 (60.2) |
CD5- positive | 4/32 (12.5) | 0/3 (0) | 0/1 (0) | 3/30 (10.0) |
R-CHOP treatment | 83/135 (61.5) | 31/42 (73.8) | 8/12 (66.7) | 78/138 (56.5) |
Death | 53/135 (39.3) | 10/42 (23.8) | 2/12 (16.7) | 90/138 (65.2) * |